Dual Vaccine Shows Strong Immune Response in Adults Over 50
A new multicomponent vaccine targeting both seasonal influenza and SARS-CoV-2 has demonstrated noninferior immunogenicity and acceptable safety in adults aged 50 years and older, according to results from a Phase III randomized trial.